CA2460587A1 - Anticorps anti-pdgf et procedes de production d'anticorps mis au point - Google Patents

Anticorps anti-pdgf et procedes de production d'anticorps mis au point Download PDF

Info

Publication number
CA2460587A1
CA2460587A1 CA002460587A CA2460587A CA2460587A1 CA 2460587 A1 CA2460587 A1 CA 2460587A1 CA 002460587 A CA002460587 A CA 002460587A CA 2460587 A CA2460587 A CA 2460587A CA 2460587 A1 CA2460587 A1 CA 2460587A1
Authority
CA
Canada
Prior art keywords
antibody
sequence
library
panel
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460587A
Other languages
English (en)
Inventor
Katherine S. Bowdish
Shana Frederickson
Anke Kretz-Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460587A1 publication Critical patent/CA2460587A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés de production et de sélection d'anticorps et/ou de fragments d'anticorps mis au point, qui permettent d'obtenir une affinité de liaison maximisée pour une cible prédéterminée, et une immunogénicité réduite au minimum lorsque de tels anticorps sont administrés à une espèce cible. L'invention concerne également des banques contenant des variants desdits anticorps mis au point. Selon des modes de réalisation particulièrement utiles, des procédés permettent d'obtenir des compositions et des anticorps anti-PGDF qui sont utiles à des fins de traitement de divers cancers.
CA002460587A 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point Abandoned CA2460587A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32354401P 2001-09-20 2001-09-20
US32353701P 2001-09-20 2001-09-20
US60/323,544 2001-09-20
US60/323,537 2001-09-20
US37999402P 2002-05-13 2002-05-13
US60/379,980 2002-05-13
PCT/US2002/030086 WO2003025019A1 (fr) 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point

Publications (1)

Publication Number Publication Date
CA2460587A1 true CA2460587A1 (fr) 2003-03-27

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460587A Abandoned CA2460587A1 (fr) 2001-09-20 2002-09-20 Anticorps anti-pdgf et procedes de production d'anticorps mis au point

Country Status (4)

Country Link
EP (1) EP1436329A4 (fr)
JP (1) JP2005512962A (fr)
CA (1) CA2460587A1 (fr)
WO (1) WO2003025019A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
WO2003048321A2 (fr) 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Anticorps hybrides
AU2003213022A1 (en) * 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
WO2004094473A2 (fr) * 2003-04-23 2004-11-04 Medarex, Inc. Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
AU2005227326B2 (en) * 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2280997A2 (fr) * 2008-04-18 2011-02-09 Xencor, Inc. Anticorps monoclonaux d équivalent humain conçus à partir de régions variables non humaines
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
EP2401614A1 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
EA030828B1 (ru) 2012-03-15 2018-10-31 Янссен Байотек, Инк. Человеческие антитела к cd27, методы и применение
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2014001442A1 (fr) * 2012-06-28 2014-01-03 Molecular Partners Ag Conception de protéines à motifs ankyrine répétés liées au facteur de croissance dérivé des plaquettes
CN104812397A (zh) 2012-09-27 2015-07-29 阿勒根公司 用于持续释放蛋白质的生物可降解的药物递送系统
KR20150128857A (ko) 2013-03-14 2015-11-18 알러간, 인코포레이티드 지속된-방출 전달의 조성물 및 제조 공정 동안 단백질을 안정화시키는 방법
BR112016000546A2 (pt) 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU1454199A (en) * 1997-11-07 1999-05-31 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
ES2375931T3 (es) * 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.

Also Published As

Publication number Publication date
JP2005512962A (ja) 2005-05-12
WO2003025019A9 (fr) 2004-05-06
WO2003025019A1 (fr) 2003-03-27
WO2003025019A8 (fr) 2004-04-01
EP1436329A1 (fr) 2004-07-14
EP1436329A4 (fr) 2005-04-27

Similar Documents

Publication Publication Date Title
US20030219839A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
CA2460587A1 (fr) Anticorps anti-pdgf et procedes de production d'anticorps mis au point
Schier et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection
JP5685274B2 (ja) 結合タンパク質の混合物
US20180002405A1 (en) Method for selecting a single cell expressing a heterogeneous combination of antibodies
JP5587280B2 (ja) 抗体のヒト化
US7060269B1 (en) Anti-VEGF antibodies
Finlay et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions
EP1054018B1 (fr) Banques de fragments Fab et leurs procédes d'utilisation
JP5153613B2 (ja) 抗体のフレームワーク・シャッフル
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
KR20010006340A (ko) 항-인간항원 수용체의 신규한 제조방법 및 용도
JP2010260845A (ja) Ｍｎ結合および細胞接着中和活性を有するヒト抗体
EP2986640B1 (fr) Anticorps humanisés contre l'interleukine 20 et traitement pour maladies inflammatoires
US20190031770A1 (en) Intercalated single-chain variable fragments
Fuh Synthetic antibodies as therapeutics
US20060024666A1 (en) Humanized antibodies against the venezuelan equine encephalitis virus
Nathan et al. Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin
AU2002341785A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
Sanlav et al. A Review on The Development, Production Strategies, and Utilization of Monoclonal Antibodies
JP2012527878A (ja) 抗原結合タンパク質
EP1747015B1 (fr) Méthode de sélection par biopanning utilisant des protéines leurres modifiées
US20230027730A1 (en) Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
JT George et al. Section Review Biologicals & Immunologicals: Advances in antibody engineering
WO2023161448A1 (fr) Protéines de liaison à une cible de type humain

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20080922